FR11C0036I1 - Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre - Google Patents

Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre

Info

Publication number
FR11C0036I1
FR11C0036I1 FR11C0036C FR11C0036C FR11C0036I1 FR 11C0036 I1 FR11C0036 I1 FR 11C0036I1 FR 11C0036 C FR11C0036 C FR 11C0036C FR 11C0036 C FR11C0036 C FR 11C0036C FR 11C0036 I1 FR11C0036 I1 FR 11C0036I1
Authority
FR
France
Prior art keywords
pharmaceutical compositions
compositions containing
receptor agonist
sugar alcohol
solid pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR11C0036C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Tanabe Seiyaku Co Ltd
Original Assignee
Novartis AG
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR11C0036(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG, Tanabe Seiyaku Co Ltd filed Critical Novartis AG
Publication of FR11C0036I1 publication Critical patent/FR11C0036I1/fr
Application granted granted Critical
Publication of FR11C0036I2 publication Critical patent/FR11C0036I2/fr
Active legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
FR11C0036C 2003-04-08 2011-09-08 Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre Active FR11C0036I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08
PCT/EP2004/003656 WO2004089341A1 (fr) 2003-04-08 2004-04-06 Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre

Publications (2)

Publication Number Publication Date
FR11C0036I1 true FR11C0036I1 (fr) 2011-10-14
FR11C0036I2 FR11C0036I2 (fr) 2023-12-29

Family

ID=32326722

Family Applications (2)

Application Number Title Priority Date Filing Date
FR0450692A Expired - Lifetime FR2854073B1 (fr) 2003-04-08 2004-04-06 Composition pharmaceutique solide comprenant un agoniste du recepteur s1p et un alcool de sucre
FR11C0036C Active FR11C0036I2 (fr) 2003-04-08 2011-09-08 Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR0450692A Expired - Lifetime FR2854073B1 (fr) 2003-04-08 2004-04-06 Composition pharmaceutique solide comprenant un agoniste du recepteur s1p et un alcool de sucre

Country Status (42)

Country Link
US (11) US20060275357A1 (fr)
EP (5) EP2319502A1 (fr)
JP (3) JP5495467B2 (fr)
KR (3) KR101367574B1 (fr)
CN (2) CN1767819B (fr)
AR (3) AR043987A1 (fr)
AT (3) AT501681B1 (fr)
AU (1) AU2004228929B2 (fr)
BE (2) BE1015972A5 (fr)
BR (1) BRPI0409250B8 (fr)
CA (2) CA2521325C (fr)
CL (2) CL2004000745A1 (fr)
CY (3) CY1110260T1 (fr)
DE (4) DE602004017847D1 (fr)
DK (2) DK1613288T3 (fr)
EC (1) ECSP056090A (fr)
ES (3) ES2228282B1 (fr)
FR (2) FR2854073B1 (fr)
GB (1) GB2400318B (fr)
GR (1) GR1005052B (fr)
HK (3) HK1071685A1 (fr)
HR (3) HRP20050886B1 (fr)
HU (2) HUE028247T2 (fr)
IL (3) IL170888A (fr)
IS (2) IS2682B (fr)
IT (1) ITMI20040682A1 (fr)
LU (1) LU91867I2 (fr)
MA (1) MA27729A1 (fr)
MX (1) MXPA05010860A (fr)
MY (1) MY141249A (fr)
NO (4) NO329332B1 (fr)
NZ (3) NZ592339A (fr)
PE (5) PE20150676A1 (fr)
PL (2) PL2316431T3 (fr)
PT (1) PT1613288E (fr)
RU (5) RU2358716C2 (fr)
SG (1) SG175449A1 (fr)
SI (2) SI2316431T1 (fr)
TN (1) TNSN05256A1 (fr)
TW (1) TWI332847B (fr)
WO (1) WO2004089341A1 (fr)
ZA (1) ZA200507394B (fr)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080096972A1 (en) * 2004-07-30 2008-04-24 Thitiwan Buranachokpaisan Compound formulations of 2-amino-1, 3-propanediol compounds
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
ES2357426T3 (es) * 2005-09-09 2011-04-26 Novartis Ag Tratamiento de enfermedades autoinmunes.
NZ595196A (en) 2005-11-09 2013-03-28 Proteolix Inc Peptide-based compounds for enzyme inhibition
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
PL2041158T3 (pl) 2006-06-19 2013-08-30 Onyx Therapeutics Inc Peptydowe epoksyketony do hamowania proteasomu
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
KR102044064B1 (ko) * 2006-09-26 2019-11-12 노파르티스 아게 S1p 조정제를 포함하는 제약 조성물
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP1923055A1 (fr) * 2006-09-26 2008-05-21 Novartis AG Composition pharmaceutique lyophilisée comprenant un agoniste ou modulateur de S1P
EP1905434A1 (fr) * 2006-09-26 2008-04-02 Novartis AG Compositions organiques comprenant d'un agoniste de S1P recepteur et leur utilisation therapeutique
EP1923054A1 (fr) * 2006-09-26 2008-05-21 Novartis AG Composition pharmaceutique à désintégration rapide comprenant un agoniste ou modulateur de S1P
EP1923058A1 (fr) * 2006-09-26 2008-05-21 Novartis AG Composition pharmaceutique enrobée comprenant un agoniste ou un modulateur de S1P
WO2008124210A1 (fr) * 2007-02-14 2008-10-16 Emory University Procédés et compositions destinés à traiter ou prévenir une infection en utilisant des agents de séquestration des leucocytes
HUE035990T2 (en) 2007-03-29 2018-05-28 Daiichi Sankyo Co Ltd Pharmaceutical preparation
PL2207791T5 (pl) 2007-10-04 2020-07-27 Onyx Therapeutics, Inc. Krystaliczne peptydo- epoksy ketonowe inhibitory proteazy i synteza keto-epoksydów Aminokwasowych
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
KR101600098B1 (ko) * 2007-10-12 2016-03-04 노파르티스 아게 스핑고신 1 포스페이트 (s1p) 수용체 조절제를 포함하는 조성물
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
US8476305B2 (en) 2008-02-07 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient
AU2009227629B2 (en) 2008-03-17 2014-09-04 Actelion Pharmaceuticals Ltd Dosing regimen for a selective S1P1 receptor agonist
EP2303250A1 (fr) 2008-06-20 2011-04-06 Novartis AG Compositions pédiatriques pour le traitement de la sclérose en plaques
RU2519768C2 (ru) * 2008-06-20 2014-06-20 Мерк Патент Гмбх Поддающаяся прямому прессованию и быстро распадающаяся матрица таблетки
CA2735037C (fr) * 2008-09-04 2016-07-12 Cargill Incorporated Compression de l'erythritol
AP2011005690A0 (en) 2008-10-21 2011-06-30 Onyx Therapeutics Inc Combination therapy with peptide epoxyketones.
BRPI0921533A2 (pt) 2008-11-11 2016-01-12 Novartis Ag composto orgânicos
ES2643161T3 (es) * 2008-11-11 2017-11-21 Novartis Ag Formas cristalinas de HCL de fingolimod
AU2013100531B4 (en) * 2008-11-11 2013-11-28 Novartis Ag Crystalline forms of fingolimod HCL
CN102256984B (zh) 2008-12-17 2014-09-03 第一三共株式会社 制备二胺衍生物的方法
WO2010082531A1 (fr) 2009-01-13 2010-07-22 第一三共株式会社 Inhibiteur d'un facteur actif de la coagulation sanguine
ES2542236T3 (es) 2009-03-10 2015-08-03 Daiichi Sankyo Company, Limited Procedimiento de producción de un derivado de diamina
CN102348680B (zh) 2009-03-13 2014-11-05 第一三共株式会社 用于制备光学活性二胺衍生物的方法
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
BRPI1011804A2 (pt) * 2009-06-18 2018-02-27 Daiichi Sankyo Company, Limited composição farmacêutica com solubilidade melhorada
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. 転移抑制のためのペプチドエポキシケトンの使用
BR112012022060A2 (pt) 2010-03-01 2018-05-08 Onyx Therapeutics Inc composto para a inibição de imunoproteassoma
CN102791719B (zh) 2010-03-19 2015-07-29 第一三共株式会社 二胺衍生物的晶体及其制备方法
WO2011115067A1 (fr) 2010-03-19 2011-09-22 第一三共株式会社 Procédé d'amélioration de l'aptitude à se dissoudre d'un anticoagulant
CA2797029A1 (fr) * 2010-04-22 2011-10-27 Ratiopharm Gmbh Procede de preparation d'une forme galenique orale comprenant du fingolimod
KR101795096B1 (ko) 2010-07-02 2017-12-01 다이이찌 산쿄 가부시키가이샤 광학 활성 디아민 유도체의 염의 제조 방법
US9266816B2 (en) 2010-11-25 2016-02-23 Shilpa Medicare Limited Fingolimod polymorphs and their processes
WO2012100043A2 (fr) 2011-01-19 2012-07-26 Pathlogica LLC Formes posologiques pharmaceutiques orales à libération contrôlée comprenant de la mgbg
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
WO2013019872A1 (fr) 2011-08-01 2013-02-07 Teva Pharmaceutical Industries Ltd. Procédé de préparation de compositions pharmaceutiques comprenant du fingolimod
KR101940840B1 (ko) 2011-08-10 2019-01-21 다이이찌 산쿄 가부시키가이샤 디아민 유도체 함유 의약 조성물
WO2013091704A1 (fr) 2011-12-22 2013-06-27 Synthon Bv Composition pharmaceutique comprenant le fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
JP2015524394A (ja) 2012-07-09 2015-08-24 オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
ES2859553T3 (es) 2013-01-08 2021-10-04 Pathologica Llc Mitoguazona para el tratamiento de esclerosis múltiple progresiva
WO2014141298A2 (fr) * 2013-03-11 2014-09-18 Astron Research Limited Composition pharmaceutique stable de fingolimod
JP6294872B2 (ja) * 2013-04-26 2018-03-14 国立大学法人京都大学 脳動脈瘤の形成および/または増大の抑制若しくは縮小用医薬組成物
MX370184B (es) * 2013-05-13 2019-12-04 Synthon Bv Composición farmacéutica que comprende fingolimod.
EP3027174B1 (fr) 2013-07-29 2019-07-24 Aizant Drug Research Solutions Private Limited Compositions pharmaceutiques à base de fingolimod
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
WO2016026461A1 (fr) * 2014-08-22 2016-02-25 Sunshine Lake Pharma Co., Ltd. Composition solide de fingolimod et préparation associée
WO2016042493A1 (fr) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Compositions pharmaceutiques de fingolimod
CA2974375A1 (fr) * 2015-01-20 2016-07-28 Handa Pharmaceuticals, Llc Forme galenique solide stable de fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
EP3419607B1 (fr) 2017-03-29 2019-11-20 Deva Holding Anonim Sirketi Formulations stables de fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) * 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja) 2020-05-18 2024-06-20 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
EP4181906A1 (fr) 2020-07-16 2023-05-24 Harbins Ruhr Bioscience, Inc. Composés sphingoïdes à utiliser dans la prophylaxie et/ou la thérapie d'une infection par un coronavirus

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
DE122011100012I1 (de) * 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-Amino-1, 3-propandiolverbindung und immunosuppressium.
DE69524962T4 (de) 1994-08-22 2003-08-28 Mitsubishi Pharma Corp., Osaka Benzolderivate und deren medizinische verwendung
SK282225B6 (sk) 1995-12-28 2001-12-03 Welfide Corporation Použitie 2-amino-2[2-(4-oktylfenyl)etyl]-propán-1,3-diolu alebo jeho farmaceuticky prijateľnej adičnej soli s kyselinou na výrobu farmaceutického prostriedku
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
JP2002241272A (ja) 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
PT990440E (pt) * 1997-02-27 2009-02-05 Novartis Ag Composição farmacêutica compreendendo 2-amino-2-[2-(4-octilfenil)etil]propano-1,3-diol, uma lecitina e um sacárido
WO1998045249A1 (fr) * 1997-04-04 1998-10-15 Yoshitomi Pharmaceutical Industries, Ltd. Composes 2-aminopropane-1,3-diol, leur utilisation pharmaceutique, et intermediaires servant a leur synthese
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) * 1999-06-30 2011-02-09 松森  昭 ウイルス性心筋炎の予防または治療薬剤
KR20020027463A (ko) * 1999-07-12 2002-04-13 우에노 도시오 스핀고신-1-인산 수용체 아고니스트 또는스핀고신-1-인산을 유효 성분으로서 함유하는 선유화 억제제
NZ523554A (en) 2000-07-13 2004-12-24 Sankyo Co Amino alcohol derivatives
AU2001285331B2 (en) * 2000-08-31 2006-04-06 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
DE60208355T2 (de) 2001-03-26 2006-07-27 Novartis Ag 2-amino-propanol derivate
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
US20040235794A1 (en) 2001-09-04 2004-11-25 Shinji Nakade Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
JP4152884B2 (ja) 2001-09-27 2008-09-17 杏林製薬株式会社 ジアリールエーテル誘導体とその付加塩及び免疫抑制剤
CN1329372C (zh) 2001-09-27 2007-08-01 杏林制药株式会社 二芳基硫醚衍生物及其加成盐和免疫抑制剂
US7479504B2 (en) 2002-01-18 2009-01-20 Merck & Co., Inc. Edg receptor agonists
AU2003216054B2 (en) 2002-01-18 2007-01-04 Merck & Co., Inc. Selective S1P1/Edg1 receptor agonists
AU2003214873A1 (en) 2002-01-18 2003-09-02 Ceretek Llc Methods of treating conditions associated with an edg receptor
AU2003202994B2 (en) 2002-01-18 2007-11-22 Merck Sharp & Dohme Corp. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
EP1772145B1 (fr) * 2004-07-16 2011-03-23 Kyorin Pharmaceutical Co., Ltd. Procédé d'utilisation efficace d'un médicament et procédé concernant la prévention d'effets secondaires

Also Published As

Publication number Publication date
US20220031609A1 (en) 2022-02-03
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
EP2008650A3 (fr) 2011-04-27
RU2009105403A (ru) 2010-08-27
US20200237690A1 (en) 2020-07-30
ES2228282B1 (es) 2006-02-16
KR101367574B1 (ko) 2014-02-25
HRP20100601B1 (hr) 2016-12-02
EP1613288A1 (fr) 2006-01-11
PE20050396A1 (es) 2005-07-05
NO20055231D0 (no) 2005-11-07
NO20131287L (no) 2006-01-09
BRPI0409250B1 (pt) 2017-07-11
BRPI0409250A (pt) 2006-03-28
PE20130200A1 (es) 2013-03-09
MY141249A (en) 2010-03-31
RU2475236C2 (ru) 2013-02-20
FR2854073B1 (fr) 2008-03-14
ES2228282A1 (es) 2005-04-01
AT504853A2 (de) 2008-08-15
RU2358716C2 (ru) 2009-06-20
GR20040100121A (el) 2004-12-17
AT501681A1 (de) 2006-10-15
US20090203798A1 (en) 2009-08-13
US20190175527A1 (en) 2019-06-13
AU2004228929A1 (en) 2004-10-21
DK1613288T3 (da) 2009-03-23
CA2521325A1 (fr) 2004-10-21
US20060275357A1 (en) 2006-12-07
NO329332B1 (no) 2010-09-27
AU2004228929B2 (en) 2008-02-07
NO2011016I1 (no) 2011-09-19
MXPA05010860A (es) 2006-05-25
LU91867I9 (fr) 2019-01-03
US20140011885A1 (en) 2014-01-09
PT1613288E (pt) 2009-02-25
EP2769713A1 (fr) 2014-08-27
CY1117071T1 (el) 2017-04-05
KR20050121712A (ko) 2005-12-27
FR11C0036I2 (fr) 2023-12-29
RU2012148593A (ru) 2014-05-20
IL170888A (en) 2010-06-16
PE20150676A1 (es) 2015-05-17
DE602004017847D1 (de) 2009-01-02
IE20040246A1 (en) 2004-12-15
GB2400318A (en) 2004-10-13
BRPI0409250B8 (pt) 2022-01-18
CL2004000745A1 (es) 2005-02-11
US20110105620A1 (en) 2011-05-05
EP2008650A2 (fr) 2008-12-31
DE202004021680U1 (de) 2010-04-22
ITMI20040682A1 (it) 2004-07-06
CY2011013I2 (el) 2014-04-09
HRP20050886A2 (en) 2006-11-30
GB2400318B (en) 2005-08-10
CN1767819A (zh) 2006-05-03
BE2011C030I2 (fr) 2023-03-07
ZA200507394B (en) 2007-03-28
RU2010147000A (ru) 2012-08-10
US20130108675A1 (en) 2013-05-02
HK1091114A1 (en) 2007-01-12
HRP20100600A2 (hr) 2011-03-31
JP2011006461A (ja) 2011-01-13
SI2316431T1 (sl) 2016-04-29
PE20131352A1 (es) 2013-11-14
DE122011100047I1 (de) 2011-12-15
CN101797241B (zh) 2013-03-27
EP2316431A1 (fr) 2011-05-04
HK1071685A1 (en) 2005-07-29
JP5543298B2 (ja) 2014-07-09
JP2004307506A (ja) 2004-11-04
CN1767819B (zh) 2010-07-28
HK1155647A1 (en) 2012-05-25
IS8114A (is) 2005-11-01
RU2475237C2 (ru) 2013-02-20
HUS1100016I1 (hu) 2016-08-29
CY1110260T1 (el) 2014-04-09
SI1613288T1 (sl) 2009-04-30
CN101797241A (zh) 2010-08-11
TNSN05256A1 (en) 2007-07-10
IL242037A0 (en) 2015-11-30
US20080311188A1 (en) 2008-12-18
TW200503784A (en) 2005-02-01
AR078781A2 (es) 2011-11-30
WO2004089341A1 (fr) 2004-10-21
NO335120B1 (no) 2014-09-22
JP2013177404A (ja) 2013-09-09
NZ542622A (en) 2009-01-31
CA2707750A1 (fr) 2004-10-21
MA27729A1 (fr) 2006-01-02
JP5495467B2 (ja) 2014-05-21
GB0407819D0 (en) 2004-05-12
DK2316431T3 (en) 2016-01-11
EP2316431B1 (fr) 2015-09-30
RU2010146697A (ru) 2012-05-27
US8324283B2 (en) 2012-12-04
NO20100250L (no) 2006-01-09
AR078782A2 (es) 2011-11-30
ES2320767T3 (es) 2009-05-28
NO334116B1 (no) 2013-12-16
ECSP056090A (es) 2006-03-01
EP2319502A1 (fr) 2011-05-11
HUE028247T2 (en) 2016-12-28
ES2556947T3 (es) 2016-01-21
KR20120101148A (ko) 2012-09-12
DE102004016947A1 (de) 2004-10-21
CA2521325C (fr) 2010-09-14
US20140255497A1 (en) 2014-09-11
EP1613288B1 (fr) 2008-11-19
IL197578A0 (en) 2011-07-31
TWI332847B (en) 2010-11-11
PE20090743A1 (es) 2009-07-17
RU2005134173A (ru) 2006-09-10
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
AT501681B1 (de) 2012-04-15
HRP20100601A2 (hr) 2011-03-31
HRP20050886B1 (en) 2011-01-31
GR1005052B (el) 2005-11-30
IL197578A (en) 2015-10-29
NZ592339A (en) 2012-09-28
NZ586280A (en) 2011-12-22
FR2854073A1 (fr) 2004-10-29
ATE414508T1 (de) 2008-12-15
IS8885A (is) 2010-02-25
LU91867I2 (fr) 2011-11-08
SG175449A1 (en) 2011-11-28
CY2011013I1 (el) 2014-04-09
IS2682B (is) 2010-10-15
NO2011016I2 (no) 2012-08-27
PL1613288T3 (pl) 2009-07-31
KR20110005320A (ko) 2011-01-17
AR043987A1 (es) 2005-08-17
US20170290787A1 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
FR11C0036I2 (fr) Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre
Giorgi et al. Pharmacokinetics of the novel atypical opioid tapentadol following oral and intravenous administration in dogs
EP1660043A4 (fr) Preparation a liberation immediate de compositions pharmaceutiques labiles en milieu acide
EE200300284A (et) NMDA-retseptori agonisti farmatseutilised kompositsioonid
ZA200801575B (en) Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
ATE354362T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
MA28527B1 (fr) Formulations orales contenant licarbazepine
MA28862B1 (fr) Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение
ITMI20061741A1 (it) Composizioni farmaceutiche per la somministrazione orale di sostanze proteiche
FR2884829B1 (fr) Procede d&#39;obtention d&#39;un extrait bacterien d&#39;aeromonas hydrophila provenant de sangsues, et compositions pharmaceutiques les contenant
DE112004002737D2 (de) Lösungsmittel für biogene pharmazeutische Wirkstoffe
AR050351A1 (es) Composiciones para el tratamiento de inflamacion y dolor usando una combinacion de un aine y un antagonista del receptor de ltb4
TH72202B (th) องค์ประกอบทางเภสัชกรรมชนิดแข็งประกอบด้วย s1p รีเซพเตอร์แอกโกนิสท์และชูการ์แอลกอฮอล์
TH70717A (th) องค์ประกอบทางเภสัชกรรมชนิดแข็งประกอบด้วย s1p รีเซพเตอร์แอกโกนิสท์และชูการ์แอลกอฮอล์
TH2523C3 (th) ผลิตภัณฑ์ น้ำยาบ้วนปากเพื่อลดความอยากอาหาร
ITMI20041849A1 (it) Formulazioni farmaceutiche per l&#39;integrazione alimentare di soggetti anoressici
DK200300002U4 (da) Farmaceutiske formuleringer indeholdende fluoxetin
DK200300003U1 (da) Farmaceutiske formuleringer indeholdende fluoxetin